Objective Jejunal interposition is an important option for restoring gastrointestinal continuity in patients with complex esophageal cancer in whom the stomach is unavailable for reconstruction due to previous gastrectomy, tumor involvement, failed gastric conduit, or other constraints. Although the jejunum offers a caliber similar to the esophagus, a rich blood supply, and preserved peristaltic function, anatomical variations in mesenteric length and vascular arcades render long-segment and high-level reconstruction susceptible to excessive tension, mesenteric torsion, venous congestion, and inadequate distal perfusion. This consensus aims to provide standardized recommendations for the application of jejunal interposition in this specific patient population. Methods This consensus was developed in accordance with the WHO Handbook for Guideline Development and Chinese national guideline development standards, with reference to the Appraisal of Guidelines for Research & Evaluation Ⅱ(AGREE Ⅱ), Reporting Items for Practice Guidelines in Healthcare (RIGHT), and Scientific, Transparent and Applicable Rankings (STAR) checklists. The project was registered on the international practice guidelines registry platform (PREPARE-2026CN1384). The working group systematically searched Chinese and English evidence addressing 12 clinical questions. Evidence was graded using the Oxford Centre for Evidence-Based Medicine (OCEBM) 2009 system, with structured appraisal of risk of bias, inconsistency, indirectness, and imprecision. Recommendations were formulated through two rounds of Delphi surveys and a face-to-face consensus meeting, with an agreement threshold of ≥75%. Results The consensus generated 12 recommendations covering indications, selection between jejunum and colon, preoperative assessment, surgical approach and reconstruction route, pedicled jejunal interposition (PJI), supercharged pedicled jejunal interposition (SPJ), indocyanine green (ICG) perfusion assessment, perioperative nutrition, management of anastomotic leakage, long-term follow-up, and special treatment scenarios. Given that the available direct evidence is predominantly derived from single-center retrospective cohorts and case series, recommendations extrapolated from general esophagectomy or other gastrointestinal surgical evidence are deliberately phrased with caution. Conclusion Jejunal interposition is a safe and effective approach for digestive tract reconstruction in patients with complex esophageal cancer in whom the stomach is unavailable. This consensus emphasizes that clinical decision-making should be individualized based on the patient's prior treatment history, reconstruction height, vascular anatomy, technical availability, and institutional experience in the Chinese context.

Helicobacter pylori(Hp)is a common pathogenic bacterium in the human digestive system.It has been classified as a group I car-cinogen by the International Agency for Research on Cancer under the World Health Organization in its published list of carcinogens.Im-munotherapy has brought new hope to patients with gastric cancer;however,in clinical practice,there are substantial individual differences in the response,and the poor therapeutic effect in some patients remains a bottleneck that urgently needs to be addressed.In recent years,a growing number of studies have shown that HP infection may be deeply involved in regulating the efficacy of gastric cancer immunother-apy through unique pathways,such as reshaping the tumor microenvironment and regulating immune checkpoint molecules expression.Re-search in this interdisciplinary field offers a new perspective on analyzing the mechanisms of immunotherapy resistance and holds import-ant exploratory value.This article systematically reviews the research progress on the impact of Hp on gastric cancer immunotherapy and its potential mechanisms,aiming to provide a theoretical basis and research directions to overcome therapeutic limitations and optimize indi-vidualized treatment strategies.

Dose fractionation of thoracic radiotherapy is a hot topic in the study of limited-stage small cell lung cancer. As a dose fractionation mode, hypofractionated thoracic radiotherapy increases the irradiation dose of each session and decreases the total irradiation sessions. It has been explored in a large number of studies, including hypofractionated thoracic radiotherapy dose escalation studies, hypofractionated and hyperfractionated comparative studies, hypofractionated and conventionally-fractionated comparative studies. Under the condition of modern chemoradiotherapy technology, compared with conventionally-fractionated and hyperfractionated protocols, hypofractionated thoracic radiotherapy has advantages in clinical application, biology and immune combination. In addition, hypofractionated thoracic radiotherapy with higher dose shows better efficacy and high safety, which may be a viable alternative to thoracic radiotherapy for limited-stage small cell lung cancer. In this article, current status and future development direction of hypofractionated thoracic radiotherapy for limited-stage small cell lung cancer were discussed.

Helicobacter pylori(Hp)is a common pathogenic bacterium in the human digestive system.It has been classified as a group I car-cinogen by the International Agency for Research on Cancer under the World Health Organization in its published list of carcinogens.Im-munotherapy has brought new hope to patients with gastric cancer;however,in clinical practice,there are substantial individual differences in the response,and the poor therapeutic effect in some patients remains a bottleneck that urgently needs to be addressed.In recent years,a growing number of studies have shown that HP infection may be deeply involved in regulating the efficacy of gastric cancer immunother-apy through unique pathways,such as reshaping the tumor microenvironment and regulating immune checkpoint molecules expression.Re-search in this interdisciplinary field offers a new perspective on analyzing the mechanisms of immunotherapy resistance and holds import-ant exploratory value.This article systematically reviews the research progress on the impact of Hp on gastric cancer immunotherapy and its potential mechanisms,aiming to provide a theoretical basis and research directions to overcome therapeutic limitations and optimize indi-vidualized treatment strategies.

Dose fractionation of thoracic radiotherapy is a hot topic in the study of limited-stage small cell lung cancer. As a dose fractionation mode, hypofractionated thoracic radiotherapy increases the irradiation dose of each session and decreases the total irradiation sessions. It has been explored in a large number of studies, including hypofractionated thoracic radiotherapy dose escalation studies, hypofractionated and hyperfractionated comparative studies, hypofractionated and conventionally-fractionated comparative studies. Under the condition of modern chemoradiotherapy technology, compared with conventionally-fractionated and hyperfractionated protocols, hypofractionated thoracic radiotherapy has advantages in clinical application, biology and immune combination. In addition, hypofractionated thoracic radiotherapy with higher dose shows better efficacy and high safety, which may be a viable alternative to thoracic radiotherapy for limited-stage small cell lung cancer. In this article, current status and future development direction of hypofractionated thoracic radiotherapy for limited-stage small cell lung cancer were discussed.

Poria cocos is a classic Chinese medicine with homology of food and medicine,which is beneficial to water infiltration,spleen and stomach,calming the heart and calming the mind,etc.It is known as"nine Poria cocos in ten prescriptions".Poria cocos contains polysaccharide,triterpenoids and steroids,among them polysaccharide and triterpenoid are considered as the main active components.Modern studies have shown that Poria cocos polysaccharide triterpenes display pharmacological activities such as anti-tumor,immunomodulatory and anti-oxidation.The dissolution rate of poria cocos and triterpenes was low in the traditional decocting process,and the oral absorption rate of poria cocos was low,but the activity of poria cocos and triterpenes was still very good,indicating the high activity of poria cocos and triterpenes.Therefore,this paper systematically reviews the extraction and separation,structural identification,content determination,structural modification,biosynthesis,pharmacological activity and potential product development value of Poria cocos polysaccharide and triterpenoids,in order to provide literature reference for the development of Poria cocos grand health industry.

At present,surgery,systemic chemotherapy,thoracic radiotherapy and prophylactic cranial irradiation have been widely recognized to treat the limited-stage small cell lung cancer.In recent decades,no significant breakthrough has been reached in drug therapy.In the field of radiotherapy,the timing,target volume,mode of dose fractionation and prophylactic cranial irradiation are the hot issues.In this article,the research progress on the dose and the mode of dose fractionation for limited-stage small cell lung cancer was briefly analyzed.

Objective: To investigate the impact of obstructive sleep apnea hypopnea syndrome (OSAHS) on platelet function in patients with ischemic stroke. Methods: Patients with ischemic stroke treated in the Department of Neurology, Weihai Municipal Hospital from January 2017 to November 2017 were collected prospectively. The presence or absence of OSAHS was determined by polysomnography. After oral administration of aspirin enteric coated tablets for 7±1 d, the maximum aggregation ratio (MAR) induced by arachidonic acid (AA) was determined by PL-12 Platelet Function Analyzer. MAR-AA ≥50% was defined as platelet hyperresponsiveness. Multivariate logistic regression analysis was used to evaluate the risk factors for platelet hyperresponsiveness in patients with ischemic stroke, and multiple linear regression analysis was used to determine the correlation between sleep parameters reflecting the severity of sleep apnea and MAR-AA. Results: Among the 124 patients with ischemic stroke, 58 (46.77%) complicated with OSAHS, 66 (53.23%) without complicated with OSAHS; 84 (67.74%) had platelet hyperresponsiveness, and 40 (32.26%) had not platelet hyperresponsiveness. MAR-AA in the complicated OSAHS group was significantly higher than that in the non-complicated OSAHS group (48.98%±20.61% vs. 26.45%±15.15%; t=-6.858, P<0.001). Multivariate logistic regression analysis showed that OSAHS was an independent risk factor for platelet hyperresponsiveness in patients with ischemic stroke (odds ratio 9.551, 95% confidence interval 3.051-29.905; P<0.001). Multiple linear regression analysis showed that there was a significant linear relationship between apnea hypopnea index and MAR-AA (β=0.499, P<0.001). Conclusions OSAHS is an independent risk factor for platelet hyperresponsiveness in patients with ischemic stroke. Apnea hypopnea index is significantly correlated with MAR-AA.

Objective To observe the changes of spleen volume in patients with acute cerebral infarction, and to explore the relationship between the spleen volume and platelet reactivity , inflammatory factors'lymphocyte subsets.Methods This is a case control study.Thirty patients with acute cerebral infarction from January 2017 to June 2017 in Department of Neurology , Weihai Municipal Hospital were included.The spleen volume, arachidonic acid-induced maximum platelet aggregation ratio ( AA-MAR), interferon gamma (IFN-γ) and lymphocyte subsets of patients were monitored in 24 hours of stroke, at 48 hours of stroke, at four days of stroke and at seven days of stroke.Twenty patients without acute cerebral infarction with the same baseline data were selected as the control group , to determine the baseline of spleen volume, AA-MAR, IFN-γand lymphocyte subsets.A t test was used to describe the changes of spleen volume, AA-MAR, IFN-γand lymphocyte subsets at different time points , and Pearson's correlation analysis was used to estimate the relationship between the spleen volume and these variables .Results Compared with the control group ((120.12 ±10.28) cm3), the patients with acute cerebral infarction in 24 hours of stroke ((117.48 ±7.93) cm3) and at 48 hours of stroke ((111.61 ±9.21) cm3) had smaller spleen volume (t＝-2.142, P＜0.05; t＝-2.790, P＜0.01), whereas at four days ((121.31 ±8.16) cm3) and seven days of stroke ((126.11 ±10.31) cm3) had bigger spleen volume (t＝2.242, P＜0.05;t＝2.762, P＜0.01), with the spleen volume decreased first and increased later.Compared with the control group, the patients with acute cerebral infarction had more AA-MAR (control group:20.97%±8.21%;24 h:31.86%±9.54%,t＝3.165,P＜0.01;48 h:41.38%±8.55%,t＝3.254,P＜0.01;4 d:35.34%± 8.15%, t＝3.203,P＜0.01;7 d:29.38% ±10.46%,t＝2.494,P＜0.05) and IFN-γ(pg/L, control group:15.21 ±5.21;24 h:29.75 ±4.57,t＝3.262,P＜0.01;48 h:43.37 ±12.15,t＝3.304,P＜0.01;4 d:40.44 ±9.86, t＝3.291,P＜0.01;7 d:20.93 ±5.51, t＝2.417,P＜0.05) at different time points, with the most AA-MAR at 48 hours of onset, and the most IFN-γat four days of stroke.Compared with the control group, the patients with acute cerebral infarction had more T 4, B lymphocytes and natural killer lymphocytes at the four time points , while the level of T8lymphocytes did not show statistically significant difference even though also increased at the four time points.The correlation analysis results showed that in patients with acute cerebral infarction , the level of AA-MAR (r＝-0.397, P＜0.05; r＝-0.515, P＜0.01; r＝-0.382, P＜0.05) and IFN-γ(r＝-0.408, P＜0.05; r＝-0.479, P＜0.01; r＝-0.378, P＜0.05) was negatively corelated with the spleen volume in 24 hours of onset, at 48 hours of stroke and at four days of stroke; the level of T4, B and natural killer lymphocytes were negatively corelated with the spleen volume in 24 hours of stroke and at 48 hours of stroke.Conclusion After the acute cerebral infarction onset, the spleen volume tends to reduce and then increases , the levels of platelet reactivity , inflammatory factors and lymphocyte subsets are correlated with the spleen volume , and the spleen may aggravate the brain injury by releasing platelets inflammatory factors and lymphocyte subsets.

Objective To identify the cross-reactive antigens shared by Mycobacteria smegmatis(MS) and Mycobacteria tuberculosis(MTB) and to analyze their antigenicity.Methods Bacterial antigens were extracted from strains of MS and MTB by ultrasonication.Western blot assay was performed to analyze common antigens that reacted with both of the antiserum samples against MS and MTB.The extracted bacterial antigens were mixed with incomplete Freund′s adjuvant and then were injected into muscles of mice.Cytokines secreted by murine spleen lymphocytes following stimulation with various antigens of MS and MTB were determined by ELISPOT and flow cytometry on the 7th day.IgG levels in serum samples were detected by ELISA 7 days after injection.Results There were cross-reactive antigens shared by MS and MTB.Potent humoral immune responses and cellular immunity against both MS and MTB could be induced by those cross-reactive antigens after sensitization the mice by either MS or MTB antigens.Cytokines of IL-2 and IFN-γ in CD4+ and CD8+T cells of mice stimulated with MS or MTB antigens were significantly increased as compared with those of non-sensitization group and those of Brucella antigens stimulation group.ConclusionCross-reactive antigens shared by MS and MTS can effectively promote specific immune reactions to the infection of MTB, which provides a scientific basis for the development of tuberculosis vaccines.